Compare PRPO & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | BEAT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 44.8M |
| IPO Year | 2000 | N/A |
| Metric | PRPO | BEAT |
|---|---|---|
| Price | $28.51 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 15.5K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,049,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $6.78 | $0.54 |
| 52 Week High | $33.63 | $4.00 |
| Indicator | PRPO | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 49.19 |
| Support Level | $25.95 | $0.91 |
| Resistance Level | $29.66 | $1.26 |
| Average True Range (ATR) | 2.29 | 0.05 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 29.53 | 91.21 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.